Progenics Pharmaceuticals Inc. picked up a worldwide partner for methylnaltrexone (MNTX), its investigational treatment of opioid-induced side effects, signing a deal with Wyeth Pharmaceuticals for up to $416 million. (BioWorld Today)

Progenics, Wyeth Sign MNTX Agreement Worth Up To $416M

Dec. 27, 2005

By Jennifer Boggs

AtheroGenics Signs Agreement With AstraZeneca For Up To $1B

Dec. 23, 2005

By Jennifer Boggs

With the end of 2005 less than two weeks away, the biggest collaborative biotech deal of the year came in just under the wire. (BioWorld Today)

AtheroGenics Signs Agreement With AstraZeneca For Up To $1B

Dec. 23, 2005

By Jennifer Boggs

With the end of 2005 less than two weeks away, the biggest collaborative biotech deal of the year came in just under the wire. (BioWorld Today)

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...